The story of Sildenafil presents a complex picture for shareholders. While the initial introduction generated significant returns, the end of its exclusive rights opened the avenue to off-brand versions, dramatically eroding market share. This creates a particular risk for drug manufacturers banking on comparable blockbuster medications, suggesting

The legacy of Viagra, and its parent company copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a deluge of knock-off medications, significantly diminishing its market share . While certain firms may seek to capitalize on similar conditions , the prese